Torrent Pharma Approves Interim Dividend of ₹29/Share; Q3 FY26 Results Announced
Torrent Pharmaceuticals announced an interim dividend of ₹29 per share, payable around March 6, 2026. The company reported Q3 FY26 standalone revenue of ₹2599 crore and net profit of ₹577 crore. Consolidated revenue was ₹3303 crore with a net profit of ₹635 crore. The acquisition and proposed merger of JB Pharma are progressing.
The interim dividend payout and the progress in the JB Pharma acquisition and merger are significant corporate actions that can impact investor sentiment and future financial performance.
The announcement of an interim dividend and positive financial results for the quarter and nine months indicate a favorable financial performance and shareholder returns.
Torrent Pharmaceuticals Limited announced its financial results for the quarter and nine months ended December 31, 2025. The Board of Directors, in their meeting held on February 13, 2026, approved audited standalone and unaudited consolidated financial results.
Key financial highlights include the declaration of an interim dividend of ₹29 (580%) per equity share of ₹5 face value, with an expected payment date around March 6, 2026. The Board meeting commenced at 2:00 pm and concluded at 4:30 pm.
The company also provided updates on its acquisition of a controlling stake in JB Pharma, detailing the share purchase agreements and regulatory approvals. The proposed merger scheme with JB Pharma is underway, with approvals pending from SEBI and subsequent filing with NCLT. The merger ratio is set at 51 equity shares of Torrent Pharma for every 100 equity shares of JB Pharma.
Financial results for the nine months ended December 31, 2025, showed total income of ₹7977 crore on a standalone basis and ₹9783 crore on a consolidated basis. Expenses for the nine months were ₹5609 crore standalone and ₹7340 crore consolidated. Profit before tax stood at ₹2305 crore standalone and ₹2366 crore consolidated. Net profit for the nine months was ₹1725 crore standalone and ₹1774 crore consolidated.
For the quarter ended December 31, 2025, standalone revenue from operations was ₹2599 crore, with a net profit of ₹577 crore. On a consolidated basis, revenue from operations was ₹3303 crore, with a net profit of ₹635 crore.
The company also reported on the repayment of listed non-convertible debentures aggregating ₹143 crore during the current quarter and noted the impact of new labor codes, stating that the incremental impact is not material.
What to do with a filing like this
Torrent Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Torrent Pharmaceuticals Limited. Read the original for the full detail.